

RIFAMPICIN-ANTIRETROVIRAL INTERACTION: DOSING CHANGE FOR NNRTI, PI, CCR5 INHIBITOR, INTEGRASE INHIBITOR

	With RIFAMPIN	With RIFABUTIN
Change in dose for NNRTI		
EFAVIRENZ	NO CHANGE (inc to 800mg if wt>60 kg)	NO CHANGE
NEVIRAPINE	NO CHANGE	NO CHANGE
DELAVIRDINE	AVOID	AVOID
ETRAVIRINE	AVOID	NO CHANGE
Change in dose for Unboosted PI		
FOSAMPRENAVIR/ ATAZANAVIR/ SAQUINAVIR	AVOID	NO CHANGE
INDINAVIR	AVOID	1000 mg q 8 hr
Change in dose for Boosted PI		
LOPINAVIR/rtv:	4 tabs q 12 or 2 tabs q 12+Ritonavir 300 mgq12hr CAUTION: HIGH RISK HEPATOTOXICITY	NO CHANGE
SAQUINAVIR/rtv	Saq 400mg/rtv 400mg q 12hr	
DARUNAVIR/rtv	AVOID	NO DATA
Change in dose for CCR5 antagonists		
MARAVIROC	Inc 600 q 12hr (use Rifabutin if possible)	NO CHANGE
Change in dose for Integrase Inhibitor		
RALTEGRAVIR	AVOID since no clinical data	NO CHANGE

ANTIRETROVIRAL-RIFAMPICIN INTERACTION: DOSING FOR RIFAMPIN / RIFABUTIN

	Change in dose for Rifampin	Change in dose for Rifabutin
EFAVIRENZ	NO CHANGE	Inc 450mg daily/600mg TIW
NEVIRAPINE	NO CHANGE	NO CHANGE
DELAVIRDINE	AVOID	AVOID
ETRAVIRINE	AVOID	DOSE BASED ON CONCOMITTANT BOOSTED PI USED
ANY UNBOOSTED PI	AVOID	Dec 150 mg qoday or qMWF
ANY BOOSTED PI	For LPV/r high dose and SQV/r dosing as listed above, no change in Rifampin. Caution: high risk hepatotoxicity. Otherwise, avoid PI with Rifampin.	Dec 150 mg qoday or qMWF
MARAVIROC	NO CHANGE	NO CHANGE
RALTEGRAVIR	NO CHANGE	NO CHANGE